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Abstract
Combinatorial therapies are required to treat patients with advanced cancers that have
become resistant to monotherapies through rewiring of redundant pathways. Due to a mas-
sive number of potential drug combinations, there is a need for systematic approaches to
identify safe and effective combinations for each patient, using cost-effective methods.
Here, we developed an exact multiobjective optimization method for identifying pairwise or
higher-order combinations that show maximal cancer-selectivity. The prioritization of
patient-specific combinations is based on Pareto-optimization in the search space spanned
by the therapeutic and nonselective effects of combinations. We demonstrate the perfor-
mance of the method in the context of BRAF-V600E melanoma treatment, where the opti-
mal solutions predicted a number of co-inhibition partners for vemurafenib, a selective
BRAF-V600E inhibitor, approved for advanced melanoma. We experimentally validated
many of the predictions in BRAF-V600E melanoma cell line, and the results suggest that
one can improve selective inhibition of BRAF-V600E melanoma cells by combinatorial tar-
geting of MAPK/ERK and other compensatory pathways using pairwise and third-order drug
combinations. Our mechanism-agnostic optimization method is widely applicable to various
cancer types, and it takes as input only measurements of a subset of pairwise drug combi-
nations, without requiring target information or genomic profiles. Such data-driven
approaches may become useful for functional precision oncology applications that go
beyond the cancer genetic dependency paradigm to optimize cancer-selective combinato-
rial treatments.
Author summary
Cancer is diagnosed in nearly 40% of people in the U.S at some point during their life-
times. Despite decades of research to lower cancer incidence and mortality, cancer
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remains a leading cause of deaths worldwide. Therefore, new targeted therapies are
required to further reduce the death rates and toxic effects of treatments. Here we devel-
oped a mathematical optimization framework for finding cancer-selective treatments that
optimally use drugs and their combinations. The method uses multiobjective optimization
to identify drug combinations that simultaneously show maximal therapeutic potential
and minimal non-selectivity, to avoid severe side effects. Our systematic search approach
is applicable to various cancer types and it enables optimization of combinations involving
both targeted therapies as well as standard chemotherapies.
Introduction
Combination therapies have become the standard of care to treat many complex diseases,
including advanced cancers, which have developed resistance to monotherapies. Due to the
heterogeneity of the disease, there is an increasing need to identify targeted combinatorial
therapies for each cancer patient individually based on patient-derived cell models, such as ex-
vivo cell cultures or patient-derived organoids and xenograft models. Systematic approaches
to finding new combinatorial treatments are often based on high-throughput screening of pre-
clinical models that emphasize combination efficacy and/or synergy as the key determinants of
the drug combination performance [1–4]. A combination is called synergistic if it has a higher
than expected effect on cancer cell inhibition, where the expected combination effect is calcu-
lated based on monotherapy responses and a reference model, such as the highest single agent,
Loewe additivity or Bliss independence [5].
The mechanistic basis of therapeutically beneficial combinations remain still poorly under-
stood, but recent findings in cancer cell line screens suggest that targets of highly synergistic
drug combinations are likely to interact at the level of signaling pathways, either targeting the
same or functionally opposite pathways, in such a way that the combined effect is greater than
the sum of the individual effects [6]. This can occur for example by combinatorial inhibition of
two orthogonal pathways or by targeting compensatory mechanisms via pathway cross-talks
[7]. However, the same combination mechanism may affect not only the cancerous cells, but
manifest itself also as unintended adverse effects in healthy cells [8]. In this case, the combina-
tion is nonselective against the particular cancer cells, and may result in a degree of toxic
effects as well. Therefore, combination synergy and expected efficacy alone are not sufficient
determinants when designing safe and effective treatment options.
Identifying cancer-selective drug combinations amounts to maximizing combination effi-
cacy in the cancer cells, while minimizing potential toxic effects to healthy cells. Such drug
combination design can be considered as a multiobjective optimization problem (MOP), in
which the two goals are pursued simultaneously [9, 10]. Even if multiobjective optimization
has been used as a tool in planning radiotherapies [11, 12], to our knowledge, the study of Mat-
lock et al. [13] is the only attempt to apply the mathematical optimization framework to
designing drug combinations. They proposed numerical algorithms that converge to most
effective and least toxic combinations of drug targets based on so-called target inhibition maps
[14]. Even though such target-centric approach provides clues about the targets to inhibit or
avoid in a given cell context, it cannot optimize the drugs to be used in the combination, and is
not applicable to non-targeted therapies, such as standard chemotherapies or emerging
immunotherapies.
In this work, we develop a novel drug-centric mathematical optimization framework for
maximizing drug combination efficacy and minimizing its nonselectivity against a given
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cancer type. Nonselectivity is defined through the average effect of a drug compound across a
large number of cells from various cancer types, and it is used as a surrogate of toxic effects.
This definition also makes it possible to apply the framework using drug sensitivity measure-
ments in the cancer cells alone, without requiring measurements on healthy cells, nor informa-
tion on targets of the drugs or genomic profiles of the cancer cells. To exemplify the
framework, we use pairwise combination measurements of 104 drug compounds in 60 cancer
cell lines from the NCI-ALMANAC resource [15], and subsequently experimentally validate
the most interesting predictions in BRAF-V600E melanoma cell line. We propose a new quan-
tity of selective synergy, Bliss multiexcess, a multiobjective generalization of the traditional
Bliss excess measure.
Results
Joint modeling of therapeutic and nonselective effects
The reduction in the rate of growth of a cell line by a drug compound is typically measured as
a growth fraction Q, the relative number of live cells with respect to untreated control after a
certain time (e.g., inhibition % after 72h of treatment). The therapeutic effect E of a drug i at
concentration ci, or a combination of a pair of drugs i, j at concentrations ci, cj, on a target cell
line l is here defined as the negative logarithm of growth fraction Q,
Eiðci; lÞ ¼   logQiðci; lÞ ð1Þ
Eijðci; cj; lÞ ¼   logQijðci; cj; lÞ : ð2Þ
Hence, the higher the therapeutic effect, the less viable the cells are after the treatment. One
advantage of the logarithmic formulation is that the effect is additive, in that the predicted
effect of two drugs acting independently, i.e. without interaction in the sense of Bliss indepen-
dence [16], is given by the sum Ei + Ej [17, 18]. We assume that higher order combination
measurements are not available, so all modeling needs to rely on the measured effects of single
drugs and pairs of drugs [19, 20]. To this end, we define the therapeutic effect of a combination
c ¼ ðciÞi2D from a set D of N possible drugs by the following pair interaction model (also


















where EXSij ðci; cj; lÞ ¼ Eijðci; cj; lÞ   Eiðci; lÞ   Ejðcj; lÞ is the effect excess of the pair over Bliss
independence model, or Bliss excess for short. The first sum in (3) yields the Bliss model effect
EB(c; l) of the combination c, and the sum over pairs of drugs is its Bliss excess EXSB ðc; lÞ.
Let m(c) = |{i: ci> 0}| denote the number of components in a drug combination c. We then
have three different types of equations for m(c) = 1, m(c) = 2, and m(c)� 2, as shown in the
following subsections.
1. Monotherapy, m(c) = 1. For a monotherapy, ci0 ¼ c for a drug i0, and ci = 0 otherwise.
The therapeutic effect in Eq (3) equals the effect of the single compound i0 at concentration c,
i.e.
Eðc; lÞ ¼ Ei0ðc; lÞ : ð4Þ
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The right-hand side equals the experimental value of E obtained from the measured growth
inhibition if data for drug i0 at concentration c exists. Otherwise, it can be obtained from
experimental results by fitting a Hill curve [24] to the other, measured concentrations (see Fig
1 and S1 Text).
2. Two-drug combination, m(c) = 2. For a combination consisting of a pair of drugs, we
have ci1 ¼ c1 and ci2 ¼ c2 for some drugs i1 and i2, and zero otherwise. Eq (3) then reads
Eðc; lÞ ¼ Ei1ðc1; lÞ þ Ei2ðc2; lÞ þ E
XS
i1 ;i2
ðc1; c2; lÞ : ð5Þ
Emergence of a Bliss excess term quantifying drug-drug interaction is a notable difference to
the corresponding formula (4) for a monotherapy. However, also in this case the right-hand
Fig 1. Selectivity analysis of the 104 individual drug compounds in NCI ALMANAC. (A) Data consists of drug sensitivity measurements of the NCI-
60 cell lines at various concentrations ci, cj of drug pairs (here vemurafenib and gefitinib, respectively). Maximal single compound activity, Qmin, of a
drug is obtained by fitting Hill curves to the dose-response data. (B) Hierarchical clustering of cell lines and drug compounds according to their Qmin.
Highly effective but nonselective drugs are clustered together and show up as dark horizontal bands in the heatmap. Leukemias (red color columns)
cluster strongly together as they are more vulnerable to a large variety of treatments than the other cancer types. Melanomas (violet columns) form one
major cluster, and the rest of the melanoma cell lines are associated with other cancer types. In particular, all but one melanoma cell line stand out from
most of the other cell lines because of their susceptibility to vemurafenib (light blue box). The drug activity profile of vemurafenib is clustered together
most closely with estramustine, an estradiol derivative with a nitrogen mustard moiety, and the anthracycline neoplastics epirubicin and idarubicin. (C)
Multiobjective optimization of single drug compounds (i.e. M = 1) acting on Malme-3M cell line. Vemurafenib is clearly the optimal single-compound
treatment because it is both effective and selective. Bortezomib and valrubicin, near the rightmost tip of the convex hull, are the least optimal drugs.
Mithramycin leads to highest therapeutic effect but it is also highly nonselective, far more than the common cytotoxic treatment cisplatin. EGFR
inhibitor gefitinib alone is not a Pareto optimal solution. The multi-coloured dots show that a substantially better efficacy can be achieved by combining
drugs. For the combination of vemurafenib and gefitinib, a higher therapeutic effect than predicted by Bliss independence model emerges, yet the boost
in efficacy comes with an increase in nonselective effect as well.
https://doi.org/10.1371/journal.pcbi.1008538.g001
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side exactly matches the experimental value obtained from measured growth inhibition if the
combinatorial growth inhibition of drug pair (i1, i2) was measured at (c1, c2). We note, how-
ever, that typically much fewer data points exist for the interaction part than for monothera-
pies, and the modeling of the combination effect is therefore more sensitive to measurement
errors.
3. Drug triplet or higher order combination, m(c)� 3. No large-scale datasets covering
majority of all combinations with at least three drug components currently exist. Therefore,
model (3) of the combination effect is based on measured pairwise effects, and the predicted









EXSj;kðcj; ck; lÞ : ð6Þ
For example, in the case m(c) = 3,
Eðc; lÞ � Ei1ðc1; lÞ þ Ei2ðc2; lÞ þ Ei3ðc3; lÞ þ E
XS
i1 ;i2
ðc1; c2; lÞ þ EXSi1 ;i3ðc1; c3; lÞ þ E
XS
i2 ;i3
ðc2; c3; lÞ : ð7Þ
The number of terms increases rapidly with an increasing m(c) because an interaction term
with all other drugs is introduced upon addition of a new drug component to a combination.
Accordingly, the effect becomes more sensitive to measurement errors.
As the level of abstraction in the modeling of the therapeutic effect changes with the num-
ber of drug components m(c), the three cases will also be discussed separately later in this
article.
Nonselective effect and multiobjective optimization
We model the nonselectivity of a drug compound by the mean effect over the set of all cell






Eðc; lÞ : ð8Þ
For a large number of patient-derived samples from various tissue types, the average in Eq (8)
comprises many somatically different cell lines. Hence, we can consider it as a proxy for the
degree of nonselective toxic effects on an average (cancerous or non-cancerous) tissue. Indeed,
it is known that widely cytotoxic (high mean effect over all the cell lines) chemotherapy drugs
display a range of severe side effects due to their poor selectivity for cancerous tissue over nor-
mal tissue [25]. On the other hand, hormonal therapies and drugs targeting cellular signaling
often have smaller mean effect, and their adverse effects are also typically more manageable. In
the S1 Appendix, we provide support to the assumption that the mean effect is a good proxy
for nonselective toxic effects, and even clinical adverse effects, therefore serving as a gauge for
combination safety.
As a drug combination should not benefit from additional drugs with hardly no effect, we
add to each �Ei a small regularizing parameter δ (we use the value 0.1) that counterbalances any
arbitrarily small increase in therapeutic effect or decrease in the mean effect. We hence define
the nonselective effect of a drug combination with m(c) components as
�EdðcÞ ¼ d �mðcÞ þ �EðcÞ : ð9Þ
In the spirit of Eq (3), the nonselective effect too can be split into nonselective effects �Ei þ d of
isolated compounds, and mean excesses �EXSij , which stem from the drug interactions.
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As the nonselective effect acts as a surrogate for adverse effects and toxicity of a combina-
tion, it makes sense to ask, which drugs or their combinations have most therapeutic potential
conditioning on a tolerance to nonselective effect. We divide the problem into parts of increas-
ing complexity by restricting the number of drug components in combinations: We first study
monotherapies only, then add in pairwise combinations, and finally allow for combinations of
any order.
Let M denote the maximal number of drugs allowed in any drug combination c, in that
m(c)�M. To find optimal combinations, with at most M components, for a cancer cell line l
that simultaneously maximize the therapeutic effect and minimize the nonselective effect is a
multi-objective optimization problem (MOP) [9, 10]. Formulated using the so-called �-con-




fargmax Eðc; lÞ : �EdðcÞ � Y;mðcÞ � Mg: ð10Þ
Here, Θ denotes the tolerance to nonselective effect, and a vector of drug concentrations that
maximizes the therapeutic effect corresponds to each Θ. The set C of solutions of this continu-
ous MOP traces, for each M, a Pareto front, a curve in the plane of nonselective and therapeutic
effects, the points of which are called Pareto optimal. For each point on the Pareto front, no
combination of drug concentrations with lower nonselective effect and higher therapeutic
effect exists when M is fixed.
Dimensional reduction by the strongest effect of a combination
The fact that the concentrations c can be adjusted on a continuous scale means that the num-
ber of solutions at the Pareto front is infinite. The Pareto front is therefore a continuous curve
in the plane of therapeutic and nonselective effects. Solving this continuum MOP is obviously
a numerically demanding task, and a successful solution very much depends on availability of
reliable combination measurements at a multitude of concentrations of all drug compounds,
so that a faithful continuous approximation to the effect in the plane of concentrations can be
found for each pair of drugs. To lower the risk of false predictions due to measurement error
and/or insufficient data resolution, we inspect a discrete set of concentrations instead. The
two-drug combination effects are typically quantified by n-by-n square matrices (e.g. n = 4, 8,
see Fig 1) with n − 1 nonzero concentrations for both drugs in a combination. However, these
concentrations are not necessarily the same for a single drug in each of those combination
measurements, which complicates the analysis. Here we choose to reduce the problem further:
We use binary variables Ni = 1 or 0, to determine whether a drug compound i 2 D is present
in the combination or not, respectively. The effect of the whole drug combination is then pre-













is the strongest effect of drug i computed from a fitted Hill curve to growth fractions Qi (see
Fig 1 and S1 Text), and, with ðc�i ; c
�
j Þ ¼ argmaxci ;cj>0Eijðci; cj; lÞ,




j ; lÞ   Eijðc
�
i ; 0; lÞ   Eijð0; c
�
j ; lÞ ð13Þ
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is the Bliss excess at the maximal measured therapeutic effect of the combination i, j. This way
of defining the parameters of the binary problem was found to constitute a robust model. In
particular, as high-throughput drug screens often show variability within and between plates
on which the cells are drugged, the strongest effect from a fitted Hill curve for each cell line
yields a reliable single number for the therapeutic effect of a drug compound in monotherapy.
Furthermore, the way the pairwise interaction constants εXSij are computed per matrix from
measurements on the same plate, and not against the fitted Hill curves, respects plate-to-plate
variance and significantly reduces the the risk of misestimating the drug interaction strengths.
In the binary model, the nonselective effect is again given by Eq (9) with the mean effect
over all cell lines computed using the binary effect function. The notions of Bliss independence
and Bliss excess of the whole combination carry over to the new definition in a natural way.
A consequence of dimensional reduction through Eqs (11–13) is that the concentration of a
drug in combination with another drug gets fixed, and a different concentration may get cho-
sen for the same drug in another pairwise combination. The combination triplet spanned by
these two pairs would then paradoxically contain a single drug in two different concentrations,
which may lead to overestimation of the combinatorial therapeutic effect. However, should
this occur, the nonselective effect is likewise affected, and the MOP is stable against these
changes.
We consider our solution to MOP a posteriori method [9], in which a human decision
maker decides, which of the Pareto optimal points provided by the algorithm are clinically rel-
evant and worth testing further in the laboratory. For example, the combinations taken into
consideration should not be much more nonselective than broadly toxic standard chemothera-
pies. Even if this condition is controlled by the nonselective effect, the set of Pareto optimal or
nearly optimal combinations may become large. Therefore ways of further delineating the ben-
efits achieved by a particular combination in comparison to other Pareto optimal solutions are
needed.
Therapeutic dominance
In multiobjective optimization, a vector is said to dominate another vector if it performs at
least equally well as the other one in all features, and it outperforms the other vector at least in
one feature [27]. Inspired by this concept, we define the therapeutic dominance of a Pareto
optimal combination:
Let E(c�) and �Edðc�Þ denote the therapeutic effect and the nonselective effect of a Pareto
optimal combination c�, respectively, and let m(c�) denote its number of components. The
therapeutic dominance of c� is defined as the difference of its therapeutic effect E(c�) and the
highest therapeutic effect of all Pareto optimal combinations with at most m(c�) − 1 compo-
nents and nonselective effect not exceeding �Edðc�Þ. This directly quantifies the therapeutic
advance gained by adding a drug to a Pareto optimal combination, or achieved by a monother-
apy in comparison to no therapy at all.
Selective synergy
A drug combination can be Pareto optimal for several reasons. First, the individual therapeutic
effects of the drug components may be strong enough to bring the combination to the Pareto
front without any synergistic interaction. In this case, the Bliss excess EXSB ðc; lÞ of the combina-
tion is small. Second, the combination may exhibit a strong effect due to synergistic interaction
of the drugs. However, synergism occurs in a large number of cell lines, leading to a compara-
ble but not excessive increase in nonselective effect. This scenario is characterized by a higher-
than-average Bliss excess, and a mean Bliss excess �EXSB ðcÞ of the same order. Third, the
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combination may show high selective synergy, in that the drug interaction is manifested as an
increase in therapeutic effect, and only little, or even as a negative change, in the mean effect
over cell lines. Selective synergy is evidenced by high Bliss excess and low mean Bliss excess.
The degree of selective synergy of a combination can be boiled down to a single number,
Bliss multiexcess
EXSB ðc; �; lÞ ¼ E
XS
B ðc; lÞ   ��E
XS
B ðcÞ ; ð14Þ
where ϕ weighs the importance of adverse effects. A motivation for definition (14), and a sys-
tematic way of choosing the value of ϕ comes from the scalarized (i.e. projected to one dimen-
sion), convex optimization problem corresponding to our MOP: Bliss multiexcess (14) equals
the interaction part of its objective function [27]
Eðc; �; lÞ ¼ Eðc; lÞ   ��EdðcÞ ; ð15Þ
which is to be maximized. Thus the combinations that are scalar-optimal for synergistic rea-
sons have high Bliss multiexcess. This argument can be extended to combinations outside the
convex hull by appropriately choosing the weighing parameter ϕ. As the Pareto optimal com-
binations near the convex hull can be seen as optional solutions to the scalarized problem, we
use a single value of ϕ for all Pareto optimal combinations between two convex solutions—the
smallest ϕ that yields the higher effect combination as an optimal solution of the scalarized
problem.
Application to melanoma
We applied the optimization framework to designing new combination therapies for malig-
nant melanoma. The optimization is based on the sensitivity data of 104 drug compounds and
their pairwise combinations in the NCI-60 cell lines available in the NCI ALMANAC resource
[28]. In this data, the drug-induced growth inhibition is tested in four-by-four matrices, as
depicted in Fig 1A. Hierarchical clustering of drug compounds and the cell lines based on
monotherapy sensitivities reveals high variation across the cell lines (Fig 1B). In particular,
vemurafenib shows a strong effect in most of the melanoma cell lines, whereas in other cancer
types the effect is less potent. This is expected, as vemurafenib is a selective inhibitor of V600E-
mutant BRAF, and this mutation is present in approximately 60% of melanomas. Vemurafenib
has become one of the main treatments for late-stage melanoma since its discovery in 2008
and consequent FDA approval in 2011 [29–31]. Despite the initial efficacy of vemurafenib in
many patients, the prognoses still remain poor as many patients develop resistance to vemura-
fenib, often within 6 to 8 months from therapy initiation, due to reactivation of the MAPK/
ERK and other pathways. This has led to interest in combinatorial inhibition of the MAPK/
ERK pathway components.
Fig 1C shows the solution of the MOP for all 104 drug compounds in the MALME-3M mel-
anoma cell line with the BRAF-V600E mutation. The Pareto front traces out the optimal com-
binations in the plane of nonselective versus therapeutic effects. Vemurafenib stands out as a
highly selective and effective treatment, as expected. Vitamin A derivative tretinoin has a lower
nonselective effect than vemurafenib, but its therapeutic effect is much smaller. On the other
hand, gefitinib, an EGFR inhibitor upstream of BRAF in the MAPK/ERK signaling pathway,
has slightly smaller therapeutic effect than vemurafenib but it is more nonselective. Notably,
the combination of vemurafenib and gefitinib (Fig 1C, top) shows an equally strong therapeu-
tic effect as the most potent monotherapy, mithramycin (plicamycin), and the combination is
synergistic, in that the effect is higher than that predicted by the Bliss independence model.
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The solutions of the MOPs for combinations of up to two drugs (Fig 2A, S1 Table) and
higher-order combinations (Fig 2B, Table 1 and S2 Table) confirm that vemurafenib-gefitinib
combination is Pareto optimal regardless of the number of components allowed in combina-
tions. Other Pareto optimal combinations involve vemurafenib with anastrozole, tretinoin,
Fig 2. (A) Multiobjective optimization (MOP) solutions for monotherapies and two-drug combinations (M = 2). Monotherapies are represented by
big monochrome dots, and multicoloured dots indicate combinations of selected compounds (see color legend). The small light blue dots represent all
the other drugs alone and in two-drug combinations. Anastrozole alone has next to no effect on any cell line, yet in combination with vemurafenib and
gefitinib, a selective effect emerges. The triplet combination of these three drugs is shown for comparison, and it yields a significant advance over all
pairs of the drugs. Pareto fronts for M = 1, 2 are shown. (B) MOP for drug triplets and their subcombinations (M = 3). Due to high number of possible
combinations, only monotherapies of drugs indicated in the legend and drug combinations involving vemurafenib, gefitinib and anastrozole are shown.
The triplet of vemurafenib and gefitinib with sirolimus is on the convex hull, indicating a strong selective effect, yet it comes with a significant cost in
nonselective effect. The Pareto front for M = 4 coincides with the one for triplets within this (and actually much wider) window of nonselective effects,
indicating that none of the fourth-order combinations perform better than drug triplets and their subcombinations.
https://doi.org/10.1371/journal.pcbi.1008538.g002





3. anastrozole + vemurafenib
4. thalidomide + vemurafenib
5. tretinoin + vemurafenib
7. sirolimus + vemurafenib
9. gefitinib + vemurafenib
Drug triplets:
6.anastrozole + thalidomide + vemurafenib
8. anastrozole + sirolimus + vemurafenib
10 anastrozole + gefitinib + vemurafenib
11 gefitinib + tretinoin + vemurafenib,
12. gefitinib + vemurafenib + vismodegib
13. gefitinib + sirolimus + vemurafenib
The numbering of combinations is the same as in Figs 2B and 3.
https://doi.org/10.1371/journal.pcbi.1008538.t001
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thalidomide and sirolimus as partners. Of these, the anti-inflammatory drug thalidomide and
the aromatase inhibitor anastrozole have little effect when used alone, indicating a true syner-
gistic interaction with vemurafenib. The same compounds appear in the Pareto optimal
combinations of three and higher order in Fig 2B. With a few exceptions, Pareto optimal com-
binations consist mostly of monotherapies and duplets at smaller therapeutic and nonselective
effects than vemurafenib-gefitinib. A cloud of triplets that all include vemurafenib and gefiti-
nib as a pairwise subcombination dominates at higher effects in Fig 2B.
Therapeutic dominance and the measure of selective synergy were used to further investi-
gate the selected combinations (Fig 3). Vemurafenib monotherapy, along with vemurafenib-
gefitinib and vemurafenib-gefitinib-sirolimus combinations are clearly the most dominant
therapies, since they yield the most therapeutic advance in comparison to a lower order Pareto
optimal combinations. However, such advance can be associated with a significant increase in
nonselective effect in the case of combinations. For instance, the duplet of vemurafenib and
gefitinib is synergistic, but not selectively synergistic. The vemurafenib duplets with anastro-
zole, thalidomide, tretinoin and sirolimus, and the triplets of vemurafenib, gefitinib and ana-
strozole, or sirolimus are truly selectively synergistic combinations with significant therapeutic
dominance over their lower order combinations.
In-house validations. To further test the most interesting predictions from the MOP
solution, we experimentally validated in-house two Pareto optimal drug triplets and their
subcombinations in the BRAF-V600E melanoma cell line MALME-3M. This validation exper-
iment was performed to test the accuracy of the predicted therapeutic effect in other experi-
mental assay (FIMM) than that used for model predictions (NCI-60). The in-house drug
combination assay was performed in 8x8 matrix format, similar to previous studies (25) (see
Materials and methods for details and S1 Fig for an example).
Table 2 shows the maximal effect over the measured concentrations in both assays. In
accord to predictions, the triplet combinations tested in-house (EFIMM) show stronger effect
than any of the duplets, and the observed therapeutic effects of triplets are very close to the pre-
dicted values (ENCI). The vemurafenib monotherapy and its combinations with gefitinib had
stronger effects in FIMM assay than those reported in NCI ALMANAC. This makes the Bliss
excesses smaller in the in-house assays. However, as the concentration of the third component
Fig 3. Therapeutic dominance (bars, left y-axis) and selective synergy measured by the Bliss multiexcess (red curve, right y-axis) of Pareto
optimal combinations as a function of nonselective effect. The numbered combinations correspond to Pareto optimal combinations highlighted in
Fig 2B, from tretinoin (1) monotherapy to vemurarfenib+gefitinib+sirolimus (13) triplet. Vemurafenib monotherapy (2) is dominant at low mean
effect. Vemurafenib + gefitinib (9) duplet has high a dominance but very low selective synergy, indicating that the combination is optimal because of its
strong therapeutic effect, not due to selective drug interaction. The combination vemurafenib+gefitinib+sirolimus (13) has the highest selective synergy
among shown combinations. The combinations vemurafenib+anastrozole (3) and vemurafenib+gefitinib+anastrozole (10) exhibit both considerable
dominance and local maxima in selective synergy.
https://doi.org/10.1371/journal.pcbi.1008538.g003
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was fixed in the in-house assays, we lack the full three-dimensional optimization over concen-
trations, and hence the most synergistic vectors may have been missed.
As the pairwise matrices in our in-house experiments have higher resolution (8x8) than in
the NCI ALMANAC assays (4x4), we were able to observe interesting nonlinearities in the
growth inhibition patterns. For example, the combination of vemurafenib and gefitinib shows
antagonistic pattern at high concentrations of vemurafenib and low concentrations of gefiti-
nib, while it results in a synergistic effect at high concentrations of both components (see S2
Fig). Further, the experiments revealed a highly synergistic combination between gefitinib and
vismodegib, a SMO inhibitor of the hedgehog pathway, and this combination scores high also
in our MOP solution because of this synergy along the high additive effect and nonselective
synergy of vemurafenib and gefitinib.
Discussion
We introduced a multiobjective optimization framework for designing effective and safe drug
combinations by simultaneous optimization of therapeutic and nonselective effects. The MOP
approach requires only the measurements of single drugs and a subset of their pairwise combi-
nations, and it enables optimization of also higher-order combinatorial treatments of three or
more drugs that are often required for treating advanced cancers. The nonselectivity was mod-
eled here by the mean effect over all the cell lines in the NCI ALMANAC data set, yet any
other control data can be used for the purpose of estimating toxic side effects. The exact MOP
solutions from Pareto-optimization provide the decision maker with a targeted set of patient-
specific combinations, illustrated and quantified by their therapeutic and nonselective effects.
We further defined Bliss multiexcess, a multiobjective generalization of the traditional Bliss
excess, as a new measure of selective synergy, and demonstrated how it enables one to solve
two critical challenges of combinatorial therapeutics: (i) combinatorial explosion of the num-
ber of potential higher-order combinations to consider for a given patient, and (ii) optimiza-
tion of the balance between therapeutic and nonselective effects to rule out broadly toxic
combinations.
Our results confirmed the previously suggested combinatorial inhibition of the MAPK/
ERK pathway as an effective and safe treatment for malignant melanoma with BRAF V600E
Table 2. NCI ALMANAC and FIMM drug assays on MALME-3M.
Treatment ENCI EXSB;NCI EFIMM EXSB;FIMM
vemurafenib 1.60 - 2.10(10) -
gefitinib 1.13 - 1.39(6) -
anastrozole 0.02 - 0.02(1) -
vismodegib 0.04 - 0.03(1) -
vem+gef 2.99 0.26 3.57 0.08
vem+ana 1.91 0.29 2.33 0.21
vem+vis 1.53 -0.11 2.41 0.28
gef+ana 1.57 0.42 1.73 0.32
gef+vis 2.13 0.96 2.15 0.73
vem+gef+ana(1 μM) 3.73 0.98 3.74 0.23
vem+gef+vis(1 μM) 3.89 1.12 3.73 0.21
ENCI: Therapeutic effect predicted by the binary pair interaction model based on NCI ALMANAC data.
EFIMM: Therapeutic effect measured at FIMM. The figure in parenthesis is the error of the last digit from fitting the Hill curve.
EXSB : Bliss excesses computed either from the first or the third column.
https://doi.org/10.1371/journal.pcbi.1008538.t002
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mutation. However, we note that the approved combination of vemurafenib with cobimetinib
[28, 29], or with any MEK inhibitor, was not tested in the NCI ALMANAC study, but our
mechanistic-agnostic model pairs the EGFR inhibitor gefitinib with vemurafenib instead. Sev-
eral higher order combinations were also found to be Pareto optimal. Of these, an aromatase
inhibitor anastrozole is typically used to treat estrogen-responsive breast cancer, and it is
therefore quite surprising to see it having selectivity for melanoma. On the other hand, already
the unsupervised hierarchical clustering of drugs without any interaction information paired
vemurafenib with estramustine, an estrogen receptor binder. There is increasing evidence that
hormone levels play a role in the growth and progression of melanoma, although the underly-
ing mechanisms are still unclear [30]. These examples demonstrate how our MOP solutions
identify among a massive number of potential combinations those with optimal efficacy and
safety profiles that have higher likelihood of success in further pre-clinical and clinical testing.
To select the Pareto optimal multi-drug combinations without relying on approximative
modeling of combination efficacies, the current MOP framework requires as input the effica-
cies of a majority of combinations both in the target cell line and in a healthy control, or in a
sufficiently large number of other cell lines, in order to compute the nonselective effects. More
specifically, for finding the Pareto optimal drug combinations of at most M components from
a set of N drug compounds, an order of NM of measurements are required for each cell line
used in the modeling. Such large-scale drug screens currently exist for monotherapies and
two-drug combinations (M = 1, 2), and to apply the MOP framework to higher-order combi-
nations, it must be augmented with a model that predicts the higher-order combination effica-
cies. In the present work, we chose the pair interaction model that uses only the measured
efficacies of monotherapies and two-drug combinations for this purpose, but there are also
other alternatives, which may be based on pair combination efficacies [21, 22] or use addi-
tional chemical and biological information such as quantitative structure-activity relationship
analysis of the compounds, gene expression data, or signaling pathway and network annota-
tions [8, 32].
The prediction of the combination effects was based on Hill equations fitted to monother-
apy dose-response data, and pairwise Bliss excesses, to increase the model robustness against
measurement errors. Since the maximal effect Qmin of a combination may be sensitive to mea-
surement errors, alternative measures of combination efficacy, such as the mean effect over
the concentration pairs, could be used instead. However, since the most promising Pareto
optimal combinations require anyway further experimental validation over a finer grid of con-
centrations, any potential erroneous solutions based on outlier measurements can be then
identified in this validation phase. We further note that, unless the concentration vectors of
single drugs were fixed in all the dose-response measurements, even averaging of the pairwise
effects over concentrations will not completely resolve the apparent paradox, where a drug
may be present at two different concentrations in one combination. Full multiobjective opti-
mization in the space of continuous concentrations will be needed to remove the superfluous
degree of freedom, and developing for it a theoretical and numerical methodology that meets
the challenges posed by both low data resolution and possible measurement errors requires
further studies.
The multiobjective optimization framework presented in this article was designed with
high-throughput experimentation in mind. Datasets such as the NCI ALMANAC, consisting
of nearly 3 million data points, allow this kind of analysis. Even if datasets of this size are still
rare, and can be produced only with larger resources, the multiobjective optimization method
is also applicable to smaller-scale combinatorial datasets that can be produced in many labora-
tories with the help of robotic instruments, in particular if combined with pre-existing data
from other studies. There area also public resources, such as PharmacoDB [33] and
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SYNERGxDB [34], that integrate monotherapy and drug combination data from published
studies in several cancer types, and can therefore be used in the MOP approach, either as target
cell lines or as background data for toxicity modelling. Dose-reponses in normal cells can be
also used to asses the nonselective toxicity of new drugs to be incorporated in the model and in
the optimization, in those applications where such control cell lines are available.
The caveat of all the models that are based on cancer cell lines is that they are monoclonal
and miss many factors important for in vivo drug responses, including tumor microenviron-
ment. This is in contrast to real tumors, which comprise heterogeneous collections of cells
with subclonal structure. Therefore, also the response to a therapy in vivo is a mixture of
responses from the subclonal populations, bringing the total therapeutic effect closer to the
nonselective effect. The tumors grow within special microenvironments that permit carcino-
genesis and allow tumor maintenance. As a consequence, most effective combination thera-
pies, in vivo, are probably multi-targeted and attack the cancer from multiple sides by slowing
down or stopping tumor cell proliferation, by thwarting drug resistance, and by blocking the
required support coming from the tumor microenvironment [35]. Nonselectivity may thus be
advantageous in some cases. However, the complementary objectives of drug efficacy and
safety are still valid. The multiobjective method can also be extended to drug profiling data of
primary patient samples (e.g. blood cancers) or complex 3D models like organoids, co-cultures
or even tissue slices, which contain clonal heterogeneity and tumor microenvironmental struc-
ture. In particular, when considering heterogenous cell population within tumors and tumor
microenvironment one would need to design targeted drug combinations that co-inhibit only
the malignant cells and avoid severe inhibition of healthy cells. Extending the MOP formula-
tion to sub-clonal drug response data is one important future aim, once such data will become
available in larger-scale.
In summary, we have introduced a novel conceptual approach for optimizing patient-spe-
cific combinatorial treatments, and demonstrated its potential both in published large-scale
drug combination data as well as using in-house validation experiments. The approach is fast,
does not require any genomic profiling of the patient cells, is applicable to various cancer
types, and enables optimization of combinations involving both targeted therapies as well as
standard chemotherapies. We hope that the systematic optimization framework will prove use-
ful in designing new effective and safe cancer therapies to further reduce the death rates and
the toxic effects of treatments.
Materials and methods
Cell line for in-house experiments
Melanoma cell line Malme-3M (ATCC HTB-64) was purchased from ATCC. It was main-
tained at 37˚C with 5% CO2 in a humidified incubator in IMDM (Cat#12440046) supple-
mented with 20% fetal bovine serum (Cat#10270-106) and 1% Penicillin-Streptomycin
(Cat#15140-122). All the reagents were purchased from ThermoFisher Scientific for the in-
house assays.
Drug combination assays
The drug combination screening approach described previously [36] was adopted on
MALME-3M cell line. Seven different concentrations in log3-fold dilution ranging from 10
nM to 10000 nM of vemurafenib and gefitinib, vemurafenib and anastrozole, and gefitinib and
anastrozole were combined with each other in 8x8 matrix formats in duplicate. For the triple
combination, 500 nM of vemurafenib or 500 nM gefitinib or 1000 nM of anastrozole was
added to the alternate drug combination matrix (in one copy). Exactly as described above,
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another set of combination was prepared for vemurafenib, gefitinib and vismodegib. For triple
combination, 1000 nM of vismodegib was used whereas the concentrations of vemurafenib
and gefitinib were the same as mentioned above (Supplementary file drug_combo_design.
xlsx). The compounds were plated to black clear bottom 384-well plates (Corning #3764)
using an Echo 550 Liquid Handler (Labcyte). 100 μM benzethonium chloride (BzCl2) and
0.1% dimethyl sulfoxide (DMSO) were used as positive and negative controls respectively. All
subsequent liquid handling was performed using MultiFlo FX multi-mode dispenser (BioTek).
The pre-dispensed compounds were dissolved in 5 μl of culture media containing cytotoxicity
measurement reagents CellTox Green (Promega) and left in plate shaker at RT for 30 min.
Twenty microliter cell suspension (75000cells/ ml) was dispensed in the drugged plates. After
72 h incubation, cytotoxicity (fluorescence, 485/520 nm excitation/emission filters) was
recorded using PheraStar plate reader (BMG Labtech). Subsequently, 25 μl per well of CellTi-
ter-Glo (Promega) reagent was added, and after 10 min of incubation at room temperature,
luminescence (cell viability) was measured using PheraStar plate reader (BMG Labtech).
Supporting information
S1 Text. Determining the parameters of the binary model.
(PDF)
S1 Appendix. Nonselective effect and drug toxicity.
(PDF)
S1 Fig. FIMM drug combination assay example. 8-by-8 matrices were constructed from Cell
Titer-Glo readouts at concentrations 0 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1000 nM, 3000
nM and 10000 nM of each drug compound (vemurafenib and gefitinib in this example). The
plotted quantity is the effect E = −log(Q).
(TIF)
S2 Fig. Heatmap visualizations of the drug combination screening. In the in-house combi-
nation screen, seven different concentrations in log3-fold dilution ranging from 10 nM to
10000 nM of vemurafenib and gefitinib, vemurafenib and anastrozole, and gefitinib and ana-
strozole were combined with each other in 8x8 matrix formats in duplicate. For the triple com-
bination, 500 nM of vemurafenib or 500 nM gefitinib or 1000 nM of anastrozole was added to
the alternate drug combination matrix (without replicates). In the same way, another set of
combination was prepared for vemurafenib, gefitinib and vismodegib. For triple combination,
1000 nM of vismodegib was used whereas the concentrations of vemurafenib and gefitinib
were the same as mentioned above.
(TIF)
S1 Table. Pareto optimal treatments for MALME-3M when only monotherapies and drug
duplets are allowed (M = 2).
(PDF)
S2 Table. Pareto optimal treatments for MALME-3M when only drug triplets and their
subcombinations are allowed (M = 3).
(PDF)
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